Compare Globus Medical Inc. Class A Common Stock (GMED) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs VanEck Vietnam ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while VanEck Vietnam ETF trades at $16.38 (market cap $465.30M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 22× VanEck Vietnam ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and VanEck Vietnam ETF for 52 Days on average.
| GMED | VNM | |
|---|---|---|
Market Cap | $10.25B | $465.30M |
Volume | 1,108,124 | 633,123 |
Sector | Health | Sector/Thematic |
52-Week High | $96.82 | $19.80 |
52-Week Low | $58.33 | $16.34 |
Typical Hold Time | 0 Days | 52 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
VNM stock trades at $16.53, down 0.3% with a bearish technical signal from moving averages. The ETF faces sector concentration risks in real estate and financials while trading at fair valuation. Recent news highlights Vietnam's potential US trade deal progress, though the fund has underperformed despite country growth prospects.
Near-term outlook remains cautious due to technical weakness and sector headwinds. Long-term exposure to Vietnam's growth offers potential, but investors face volatility from interest rate sensitivity and concentrated sector risks. The bearish technical setup suggests continued pressure on current price levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
